DE60127583D1 - Neues verfahren zur synthese von n-phenyl-5-(4-fluorphenyl)-1-(2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl)-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäureamid - Google Patents
Neues verfahren zur synthese von n-phenyl-5-(4-fluorphenyl)-1-(2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl)-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäureamidInfo
- Publication number
- DE60127583D1 DE60127583D1 DE60127583T DE60127583T DE60127583D1 DE 60127583 D1 DE60127583 D1 DE 60127583D1 DE 60127583 T DE60127583 T DE 60127583T DE 60127583 T DE60127583 T DE 60127583T DE 60127583 D1 DE60127583 D1 DE 60127583D1
- Authority
- DE
- Germany
- Prior art keywords
- phenyl
- oxotetrahydropyran
- fluorphenyl
- carboxamide
- pyrrole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26050501P | 2001-01-09 | 2001-01-09 | |
US260505P | 2001-01-09 | ||
PCT/IB2001/002729 WO2002055519A2 (en) | 2001-01-09 | 2001-12-27 | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r, 4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60127583D1 true DE60127583D1 (de) | 2007-05-10 |
DE60127583T2 DE60127583T2 (de) | 2007-12-06 |
Family
ID=22989433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60127583T Expired - Fee Related DE60127583T2 (de) | 2001-01-09 | 2001-12-27 | Neues verfahren zur synthese von n-phenyl-5-(4-fluorphenyl)-1-(2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl)-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäureamid |
Country Status (25)
Country | Link |
---|---|
US (7) | US6476235B2 (de) |
EP (1) | EP1353917B1 (de) |
JP (2) | JP4190285B2 (de) |
KR (3) | KR100582326B1 (de) |
CN (4) | CN100351252C (de) |
AR (1) | AR035680A1 (de) |
AT (1) | ATE358126T1 (de) |
BR (1) | BR0116739A (de) |
CA (1) | CA2432064C (de) |
CY (1) | CY1106590T1 (de) |
CZ (1) | CZ20031893A3 (de) |
DE (1) | DE60127583T2 (de) |
DK (1) | DK1353917T3 (de) |
ES (1) | ES2282200T3 (de) |
HK (2) | HK1060572A1 (de) |
HU (1) | HUP0302647A3 (de) |
IL (4) | IL156461A0 (de) |
MX (1) | MXPA03005284A (de) |
PL (1) | PL365283A1 (de) |
PT (1) | PT1353917E (de) |
RU (1) | RU2244714C1 (de) |
TW (1) | TWI293073B (de) |
WO (1) | WO2002055519A2 (de) |
YU (1) | YU49003A (de) |
ZA (1) | ZA200304684B (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
IL159719A0 (en) * | 2001-07-06 | 2004-06-20 | Teva Pharma | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives |
US20060020137A1 (en) * | 2001-11-29 | 2006-01-26 | Limor Tessler | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
KR100765555B1 (ko) * | 2002-08-06 | 2007-10-09 | 워너-램버트 캄파니 엘엘씨 | 5-(4-플루오로페닐)-1-[2-((2r,4r)-4-히드록시-6-옥소-테트라히드로-피란-2-일)에틸]-2-이소프로필-4-페닐-1h-피롤-3-카르복실산 페닐아미드의 제조 방법 |
ES2287549T3 (es) | 2002-08-06 | 2007-12-16 | Warner-Lambert Company Llc | Procedimiento para preparar la fenilamida del acido 5-(4-fluorofenil)-1-(2-((2r,4r)-4-hidroxi-6-oxo-tetrahidropiran-2-il)etil)-2-isopropil-4-fenil-1h-pirrol-3-carboxilico. |
AU2003295684A1 (en) * | 2002-11-15 | 2004-06-15 | Teva Pharmaceutical Industries Ltd. | Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids |
AU2004228463A1 (en) * | 2003-04-14 | 2004-10-21 | Warner-Lambert Company Llc | Process for preparing 5-(4-fluorophenyl)-1-[2-((R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
US7166638B2 (en) | 2003-05-27 | 2007-01-23 | Nicox S.A. | Statin derivatives |
US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
US7396947B2 (en) * | 2003-06-13 | 2008-07-08 | Lanxess Deutschland Gmbh | Chiral ligands for application in asymmetric syntheses |
CA2539158A1 (en) * | 2003-09-17 | 2005-03-24 | Warner-Lambert Company Llc | Crystalline forms of ['r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid |
CN1871202A (zh) | 2003-10-24 | 2006-11-29 | 隆萨股份公司 | 6,6,6-三卤-3,5-二氧代己酸酯的制备方法 |
US20050152323A1 (en) * | 2004-01-12 | 2005-07-14 | Vincent Bonnassieux | Plug-in Wi-Fi access point device and system |
SI21745A (sl) * | 2004-04-09 | 2005-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina |
KR100829268B1 (ko) * | 2004-04-16 | 2008-05-13 | 화이자 프로덕츠 인코포레이티드 | 비정질 아토바스타틴 칼슘의 제조 방법 |
JP2007536373A (ja) | 2004-05-05 | 2007-12-13 | ファイザー・プロダクツ・インク | アトルバスタチンの塩形態 |
CZ299175B6 (cs) * | 2004-06-17 | 2008-05-07 | Zentiva, A. S | Zpusob stanovení enantiomerní cistoty 2-(4-fluorfenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-fenyl-4[(fenylamino)-karbonyl]-1H-pyrrol-1-heptanové kyseliny a jejích solí |
CA2833770A1 (en) * | 2004-07-16 | 2006-01-26 | Lek Pharmaceuticals D.D | Oxidative degradation products of atorvastatin calcium |
CA2754932C (en) | 2004-07-20 | 2014-04-01 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
NZ552632A (en) * | 2004-07-30 | 2010-11-26 | Exelixis Inc | Pyrrole derivatives as pharmaceutical agents |
KR20070067175A (ko) | 2004-10-28 | 2007-06-27 | 워너-램버트 캄파니 엘엘씨 | 무정형 아토르바스타틴 형성 방법 |
US20090088465A1 (en) * | 2004-12-02 | 2009-04-02 | Stephen Craig Dyar | Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same |
WO2006067795A2 (en) * | 2004-12-23 | 2006-06-29 | Jubilant Organosys Limited | Novel polymorphic forms of atorvastatin lactone and process for preparing the same |
ATE509009T1 (de) * | 2005-03-14 | 2011-05-15 | C P Pharmaceuticals Internat C V | Herstellung eines atorvastatin-zwischenprodukts unter anwendung einer paal-knorr-kondensation |
EP1705175A1 (de) * | 2005-03-24 | 2006-09-27 | ratiopharm GmbH | Verfahren zur Herstellung von C5-Produkten und ihre Verwendung in der Synthese von Atorvastatin |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
GB0523637D0 (en) * | 2005-11-21 | 2005-12-28 | Avecia Pharmaceuticals Ltd | Process and compounds |
DK1957452T3 (da) | 2005-11-21 | 2010-07-26 | Warner Lambert Co | Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium |
CA2652412A1 (en) * | 2006-05-15 | 2007-11-22 | Ratiopharm Gmbh | Process for preparing c5 intermediates and their use in the preparation of n-substituted pyrrole derivatives |
KR101069698B1 (ko) * | 2008-08-28 | 2011-10-04 | 한국화학연구원 | 광학 활성을 갖는 (4r, 6r)-6-(2-아미노에틸)-4-하이드록시-테트라하이드로피란-2-온 유도체의 제조방법 |
CN101429195B (zh) * | 2008-11-03 | 2010-12-15 | 华东师范大学 | 一种高纯度阿托伐他汀重要合成中间体的制备方法 |
EP2327682A1 (de) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Verwendung von amphiphilen Verbindungen zur gesteuerten Kristallisation von Statinen und Statin Zwischenprodukte. |
SI2373609T1 (sl) | 2008-12-19 | 2013-12-31 | Krka, D.D., Novo Mesto | Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov |
WO2011028309A1 (en) | 2009-09-04 | 2011-03-10 | University Of Toledo | PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY |
KR100986755B1 (ko) * | 2009-12-29 | 2010-10-08 | 김우진 | 노즐 회전장치 및 이를 갖는 분수 |
CN101892276B (zh) * | 2010-06-12 | 2012-11-21 | 郝志艳 | 一种阿托伐他汀钙化合物及其新方法 |
SI2616454T1 (sl) | 2010-09-16 | 2015-08-31 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Estri heksanojskih kislin, kot vmesne spojine za pripravo atorvastatina |
BRPI1101952B1 (pt) * | 2011-04-25 | 2022-02-01 | Universidade Estadual De Campinas - Unicamp | Processo de obtenção de atorvastatina cálcica utilizando novos intermediários e atorvastatina assim obtida |
US20140335179A1 (en) | 2011-07-01 | 2014-11-13 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Micronized crystals of atorvastatin hemicalcium |
EA201891817A1 (ru) * | 2016-02-11 | 2019-07-31 | Стихтинг Катхолике Юниверситейт | Новый класс соединений для лечения сердечно-сосудистых заболеваний |
US11657391B1 (en) | 2019-05-24 | 2023-05-23 | Hiro Systems Pbc | System and method for invoking smart contracts |
US11513815B1 (en) | 2019-05-24 | 2022-11-29 | Hiro Systems Pbc | Defining data storage within smart contracts |
US10699269B1 (en) * | 2019-05-24 | 2020-06-30 | Blockstack Pbc | System and method for smart contract publishing |
CN113559318B (zh) * | 2021-07-05 | 2022-09-13 | 四川大学 | 一种促神经功能恢复的手性导电修复支架及其制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
ES2167587T3 (es) | 1995-07-17 | 2002-05-16 | Warner Lambert Co | Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina). |
HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
WO1997037985A1 (en) * | 1996-04-10 | 1997-10-16 | Warner-Lambert Company | Nonpeptide endothelin antagonists with increased water solubility |
US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
IL127058A (en) | 1996-07-29 | 2001-07-24 | Warner Lambert Co | Process for the synthesis of protected esters of acid (S) - 4,3 dehydroxybutyric |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
-
2001
- 2001-12-17 US US10/015,558 patent/US6476235B2/en not_active Expired - Fee Related
- 2001-12-27 CZ CZ20031893A patent/CZ20031893A3/cs unknown
- 2001-12-27 KR KR1020037009159A patent/KR100582326B1/ko not_active IP Right Cessation
- 2001-12-27 KR KR1020067001883A patent/KR100677008B1/ko not_active IP Right Cessation
- 2001-12-27 HU HU0302647A patent/HUP0302647A3/hu unknown
- 2001-12-27 CN CNB2005100056012A patent/CN100351252C/zh not_active Expired - Fee Related
- 2001-12-27 JP JP2002556188A patent/JP4190285B2/ja not_active Expired - Fee Related
- 2001-12-27 YU YU49003A patent/YU49003A/sh unknown
- 2001-12-27 KR KR1020067022289A patent/KR100833911B1/ko not_active IP Right Cessation
- 2001-12-27 MX MXPA03005284A patent/MXPA03005284A/es active IP Right Grant
- 2001-12-27 EP EP01273081A patent/EP1353917B1/de not_active Expired - Lifetime
- 2001-12-27 BR BR0116739-1A patent/BR0116739A/pt not_active IP Right Cessation
- 2001-12-27 DK DK01273081T patent/DK1353917T3/da active
- 2001-12-27 WO PCT/IB2001/002729 patent/WO2002055519A2/en active Application Filing
- 2001-12-27 RU RU2003120510/04A patent/RU2244714C1/ru active
- 2001-12-27 IL IL15646101A patent/IL156461A0/xx unknown
- 2001-12-27 PL PL01365283A patent/PL365283A1/xx not_active Application Discontinuation
- 2001-12-27 CN CNA2006101006335A patent/CN1907984A/zh active Pending
- 2001-12-27 DE DE60127583T patent/DE60127583T2/de not_active Expired - Fee Related
- 2001-12-27 CA CA002432064A patent/CA2432064C/en not_active Expired - Fee Related
- 2001-12-27 PT PT01273081T patent/PT1353917E/pt unknown
- 2001-12-27 ES ES01273081T patent/ES2282200T3/es not_active Expired - Lifetime
- 2001-12-27 CN CNA2006101518437A patent/CN101024626A/zh active Pending
- 2001-12-27 AT AT01273081T patent/ATE358126T1/de not_active IP Right Cessation
- 2001-12-27 CN CNB018225098A patent/CN1222521C/zh not_active Expired - Fee Related
- 2001-12-28 TW TW090132903A patent/TWI293073B/zh active
-
2002
- 2002-01-08 AR ARP020100043A patent/AR035680A1/es not_active Application Discontinuation
- 2002-07-18 US US10/198,682 patent/US6545153B1/en not_active Expired - Fee Related
-
2003
- 2003-01-21 US US10/348,727 patent/US6933393B2/en not_active Expired - Fee Related
- 2003-06-17 ZA ZA200304684A patent/ZA200304684B/en unknown
-
2004
- 2004-05-21 HK HK04103610A patent/HK1060572A1/xx not_active IP Right Cessation
-
2005
- 2005-04-19 US US11/109,396 patent/US7183408B2/en not_active Expired - Fee Related
-
2006
- 2006-04-12 HK HK06104433A patent/HK1084114A1/xx not_active IP Right Cessation
- 2006-10-11 US US11/545,870 patent/US7399773B2/en not_active Expired - Fee Related
- 2006-10-11 US US11/545,899 patent/US7371855B2/en not_active Expired - Fee Related
- 2006-10-11 US US11/546,047 patent/US7361771B2/en not_active Expired - Fee Related
-
2007
- 2007-05-14 CY CY20071100653T patent/CY1106590T1/el unknown
- 2007-09-14 JP JP2007239659A patent/JP2008100989A/ja not_active Withdrawn
-
2008
- 2008-02-07 IL IL189359A patent/IL189359A0/en unknown
- 2008-02-07 IL IL189357A patent/IL189357A0/en unknown
- 2008-02-07 IL IL189358A patent/IL189358A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60127583D1 (de) | Neues verfahren zur synthese von n-phenyl-5-(4-fluorphenyl)-1-(2-((2r,4r)-4-hydroxy-6-oxotetrahydropyran-2-yl)ethyl)-2-isopropyl-4-phenyl-1h-pyrrol-3-carbonsäureamid | |
ATE298326T1 (de) | Verfahren zur epoxidierung von olefinen | |
ATE353322T1 (de) | Verfahren zur herstellung von 2- (chinoxalin-5- ylsulfonylamino) -benzamid-verbindungen | |
ATE437486T1 (de) | Verfahren zur konfiguration von physischen kanälen | |
ATE487709T1 (de) | Verfahren zur synthese von 5-(methyl-1h-imidazol- 1-yl)-3-(trifluormethyl)benzolamin | |
DE60327356D1 (de) | Verfahren zur synthese von metallnanoteilchen | |
DK1353923T3 (da) | Forbedret fremgangsmåde til syntese af carbapenem | |
DE602004013990D1 (de) | Ernen von spänen | |
ATE483690T1 (de) | Verfahren zur synthese von 5-(methyl-1h-imidazol- 1-yl)-3-(trifluormethyl)-benzeneamin | |
DE602004012925D1 (de) | Protokoll zur Erbringung von Diensten | |
DK1575941T3 (da) | Fremgangsmåde til fremstilling af (S)-pantoprazol | |
DE60321098D1 (de) | Verfahren zur Herstellung von Hydroxyalkyl(meth)acrylat | |
DE60113157D1 (de) | Verbessertes verfahren zur herstellung von simvastatin | |
DE60315308D1 (de) | VERFAHREN ZUR HERSTELLUNG VON 5-(4-FLUORPHENYL)-1-i2-((2R,4R)-4-HYDROXY-6-OXOTETRAHYDROPYRAN-2-YL)ETHYLö-2-ISOPROPYL-4-PHENYL-1H-PYRROL-3-CARBONSÄUREPHENYLAMID | |
DE60219746D1 (de) | Verfahren zur Herstellung von Biarylverbindungen | |
DE60325140D1 (de) | Verfahren zur Herstellung von Hydroxyalkyl(meth)acrylat | |
DE60225721D1 (de) | Verfahren zur zugriffskontrolle über spezifischen dienste via einem verteiler | |
ATE305939T1 (de) | Verfahren zur synthese von (2s,3as,7as)-1-((s)- | |
ATE306485T1 (de) | Verfahren zur herstellung von 2-(-5-(4- fluorphenyl)-3-pyridylmethylaminomethyl)-chroma | |
DE60117687D1 (de) | Verfahren zur synthese von pfropfpolymeren | |
BRPI0409333A (pt) | processo para a preparação de fenilamida do ácido 5-(4-fluorofenil)-1-[2-((2r,4r)-4-hidróxi-6-oxo-tetrahid ro-piran-2-il)etil]-2-isopropil-4-fenil-1h-pirrol-3-carb oxìlico | |
DE60108105D1 (de) | Verfahren zur Herstellung von 5-substituierten Isobenzofuranen | |
ATE280775T1 (de) | Verfahren zur synthese von (2s,3as,7as)-1-((s)- | |
ATE382035T1 (de) | Verfahren zur herstellung von n-substituierten phthalimiden | |
DE50307097D1 (de) | Katalytisches verfahren zur herstellung von carbonyl-verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: DERZEIT KEIN VERTRETER BESTELLT |
|
8339 | Ceased/non-payment of the annual fee |